Medesis Pharma Extends Collaboration in Biopharm Sector
Medesis Pharma has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies
Medesis Pharma, a biopharmaceutical company represented in France and Canada, has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies (Commissariat à l'énergie atomique et aux énergies alternatives, CEA) on the development of compounds designed to remove radioactive/toxic metal contaminants from the body.
Medesis Pharma is targeting the defense markets and the civil nuclear industry (especially governmental stocks of decorporation products for civil protection in the vicinity of nuclear power plants). At present, there are no appropriate marketed products to use on a broad population for decorporation of plutonium and cesium, and there is no treatment for the decorporation of uranium, according to the company.
"Here at Medesis Pharma, we are delighted to extend and formalize our collaboration with CEA - simply the best possible partner for many opportunities in this part of the pharmaceutical market," commented Pharma Medesis' CEO Jean-Claude Maurel.
Meanwhile, Eric Quémeneur (Program and Research Exploitation Director in the CEA's Life Sciences Department) welcomed the opportunity to jointly develop original compounds in under-explored therapeutic areas.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
